AML and high-risk MDS patients have significantly larger CD4+CD25high/CD4 and CD4+CD25highFoxP3+/CD4 populations in the periphery compared to patients with autoimmune hematologic diseases and controls, respectively. This evidence concerns the gene CD4 and myelodysplastic syndrome.